Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8783252 | Middle East Fertility Society Journal | 2017 | 5 Pages |
Abstract
This research aimed to investigate the effect of genistein on TGF-β, dysregulation of apoptosis, NF-κB pathway, COX-2 pathway in mice of endometriosis model. Twenty-eight female mice (Mus musculus) were divided into seven groups (n = 4), involving control (normal non-treated) group; endometriosis group; the endometriosis group treated with various genistein dosages (0.78; 1.04; 1.3 mg/day for 15 days), and endometriosis group treated with standard drug, namely leuprolide acetate (0.00975 mg each day for 15 days) or dienogest (0.0052 mg/day for 15 days). Mice of endometriosis model were made by implanting myometrial and endometrial tissues under the condition of immunodeficiency. The TGF-β, Bcl-2, Bax, NF-κB, COX-2, and PGE-2 were analyzed immunohistochemically. The increase of Bcl-2 expression in endometriosis was decreased significantly by genistein dosage of 0.78 and 1.3 mg/day (p < 0.05). The decrease of Bax expression in endometriosis was increased significantly by genistein dosage of 1.04 and 1.3 mg/day (p < 0.05). The implantation increased the expression of NF-κB, COX-2, and PGE significantly compared with the control group (p < 0.05). This increase was reduced significantly by the administration of genistein at dosage of 0.78 and 1.3 mg/day (p < 0.05). It can be concluded that genistein potentially inhibits endometriosis development through the normalization of apoptosis dysregulation, the inhibition of NF-κB and COX-2 pathways in the peritoneal tissues. Therefore, genistein can be used as a holistic treatment strategy for endometriosis.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Sutrisno Sutrisno, Chandra Sulistyorini, Eviyani Margaretha Manungkalit, Lilik Winarsih, Noorhamdani Noorhamdani, Sri Winarsih,